Live Breaking News & Updates on Zika virus vaccine

Stay informed with the latest breaking news from Zika virus vaccine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Zika virus vaccine and stay connected to the pulse of your community

Efforts now to develop Zika virus vaccine in India: NTAGI chief Dr NK Arora

A 5-year-old girl in Karnataka tested positive for the Zika virus and has been advised to take precautionary measures.

Karnataka , India , Zika-virus , Ntagi , Dr-nk-arora , Zika-virus-vaccine , Zika-virus-symptoms , Zika-virus-outbreak , Ntagi-chief-dr-nk-arora ,

Can Zika Virus Kill You, 4 Rare Conditions it Can Cause in Infected People

Zika Virus Symptoms: Can Zika Virus kill you - how fatal is Zika Virus - 4 rare conditions it can cause in infected people - India patients list.

Puerto-rico , Karnataka , India , Kerala , Centers-for-disease , Can-zika-virus-kill , Can-cause , Virus-symptoms , Zika-virus , Zika-virus-kill , Aedes-aegypti-mosquito

RTI Recognized by Altino Ventura Foundation for Zika Research

RESEARCH TRIANGLE PARK, N.C. — Researchers from RTI International, a nonprofit research institute, have been honored by the Altino Ventura Foundation with the 2021 Social Vision Award, recognizing the institute’s ongoing research involving children with congenital Zika syndrome and their families and caregivers.

Brazil , Anne-wheeler , Altino-ventura-foundation , Vision-award , Medical-specialties , Research , 2015-16-zika-virus-epidemic , Organisms , Zika-fever , Zika-virus , Zika-virus-vaccine ,

Aurobindo Pharma after tieup with COVAXX for COVID-19 vaccine in India

COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.Aurobindo Pharma and US-based COVAXX have entered into an exclusive license agreement to develop, commercialize and manufacture UB-612, the first multitope peptide-based vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency.
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.
Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX's vaccine candidate, UB-612. The pharmaceutical company will manufacture the finished doses at its facilities in Hyderabad (Telangana). Aurobindo Pharma has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021, the company said in a statement before market hours today, 24 December 2020.

India , Aurobindo-pharma , United-nations-children-fund , United-nations-children , Capital-market , Medicine , Vaccines , Health-sciences , Vaccination , Medical-research , Zika-virus , Zika-virus-vaccine